메뉴 건너뛰기




Volumn 70, Issue 1, 2011, Pages 157-163

Effectiveness of switching between TNF inhibitors in ankylosing spondylitis: Data from the NOR-DMARD register

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB;

EID: 78650678574     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2010.131797     Document Type: Article
Times cited : (127)

References (43)
  • 1
    • 0037029430 scopus 로고    scopus 로고
    • Treatment of active ankylosing spondylitis with infliximab: A randomised controlled multicentre trial
    • Braun J, Brandt J, Listing J, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002 ; 359 : 1187-93.
    • (2002) Lancet , vol.359 , pp. 1187-1193
    • Braun, J.1    Brandt, J.2    Listing, J.3
  • 2
    • 0037007683 scopus 로고    scopus 로고
    • Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha
    • Gorman JD, Sack KE, Davis JC Jr. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med 2002 ; 346 : 1349 - 56
    • (2002) N Engl J Med , vol.346 , pp. 1349-1356
    • Gorman, J.D.1    Sack, K.E.2    Davis Jr., J.C.3
  • 3
    • 33745894976 scopus 로고    scopus 로고
    • Efficacy and safety of adalimumab in patients with ankylosing spondylitis: Results of a multicenter, randomized, double-blind, placebo-controlled trial
    • van der Heijde D, Kivitz A, Schiff MH, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006 ; 54 : 2136-46.
    • (2006) Arthritis Rheum , vol.54 , pp. 2136-46
    • Van Der Heijde, D.1    Kivitz, A.2    Schiff, M.H.3
  • 4
    • 55849108826 scopus 로고    scopus 로고
    • Efficacy and safety of golimumab in patients with ankylosing spondylitis: Results of a randomized, double-blind, placebo-controlled, phase III trial
    • Inman RD, Davis JC, Jr, Heijde D, et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum 2008 ; 58 : 3402-12.
    • (2008) Arthritis Rheum , vol.58 , pp. 3402-3412
    • Inman, R.D.1    Davis, J.C.2    Jr Heijde, D.3
  • 5
    • 34247853488 scopus 로고    scopus 로고
    • Drug insight: Different mechanisms of action of tumor necrosis factor antagonists-passive-aggressive behavior?
    • Rigby WF. Drug insight: different mechanisms of action of tumor necrosis factor antagonists-passive-aggressive behavior? Nat Clin Pract Rheumatol 2007 ; 3 : 227-33.
    • (2007) Nat Clin Pract Rheumatol , vol.3 , pp. 227-233
    • Rigby, W.F.1
  • 6
    • 34548159935 scopus 로고    scopus 로고
    • Do rheumatoid arthritis patients in clinical practice benefit from switching from infliximab to a second tumor necrosis factor alpha inhibitor?
    • Hjardem E, Østergaard M, Pødenphant J, et al. Do rheumatoid arthritis patients in clinical practice benefit from switching from infliximab to a second tumor necrosis factor alpha inhibitor? Ann Rheum Dis 2007 ; 66 : 1184-9.
    • (2007) Ann Rheum Dis , vol.66 , pp. 1184-1189
    • Hjardem, E.1    Østergaard, M.2    Pødenphant, J.3
  • 7
    • 27544437514 scopus 로고    scopus 로고
    • Adalimumab (Humira) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade) or etanercept (Enbrel): Results from the STURE registry at Karolinska University Hospital
    • Wick MC, Ernestam S, Lindblad S, et al. Adalimumab (Humira) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade) or etanercept (Enbrel): results from the STURE registry at Karolinska University Hospital. Scand J Rheumatol 2005 ; 34 : 353-8.
    • (2005) Scand J Rheumatol , vol.34 , pp. 353-358
    • Wick, M.C.1    Ernestam, S.2    Lindblad, S.3
  • 8
    • 10044253359 scopus 로고    scopus 로고
    • Clinical outcomes of patients with rheumatoid arthritis after switching from infliximab to etanercept
    • Haraoui B, Keystone EC, Thorne JC, et al. Clinical outcomes of patients with rheumatoid arthritis after switching from infliximab to etanercept. J Rheumatol 2004 ; 31 : 2356-9.
    • (2004) J Rheumatol , vol.31 , pp. 2356-2359
    • Haraoui, B.1    Keystone, E.C.2    Thorne, J.C.3
  • 9
    • 33846239331 scopus 로고    scopus 로고
    • Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: Results from a large UK national cohort study
    • Hyrich KL, Lunt M, Watson KD, et al. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum 2007 ; 56 : 13-20.
    • (2007) Arthritis Rheum , vol.56 , pp. 13-20
    • Hyrich, K.L.1    Lunt, M.2    Watson, K.D.3
  • 10
    • 24944490986 scopus 로고    scopus 로고
    • Adalimumab in clinical practice. Outcome in 70 rheumatoid arthritis patients, including comparison of patients with and without previous anti-TNF exposure
    • Bennett AN, Peterson P, Zain A, et al. Adalimumab in clinical practice. Outcome in 70 rheumatoid arthritis patients, including comparison of patients with and without previous anti-TNF exposure. Rheumatology 2005 ; 44 : 1026-31.
    • (2005) Rheumatology , vol.44 , pp. 1026-1031
    • Bennett, A.N.1    Peterson, P.2    Zain, A.3
  • 11
    • 0242609073 scopus 로고    scopus 로고
    • Do the clinical responses and complications following etanercept or infliximab therapy predict similar outcomes with the other tumor necrosis factor-alpha antagonists in patients with rheumatoid arthritis?
    • Ang HT, Helfgott S. Do the clinical responses and complications following etanercept or infliximab therapy predict similar outcomes with the other tumor necrosis factor-alpha antagonists in patients with rheumatoid arthritis? J Rheumatol 2003 ; 30 : 2315-18.
    • (2003) J Rheumatol , vol.30 , pp. 2315-2318
    • Ang, H.T.1    Helfgott, S.2
  • 12
    • 29944442627 scopus 로고    scopus 로고
    • The efficiency of switching from infliximab to etanercept and vice-versa in patients with rheumatoid arthritis
    • Cohen G, Courvoisier N, Cohen JD, et al. The efficiency of switching from infliximab to etanercept and vice-versa in patients with rheumatoid arthritis. Clin Exp Rheumatol 2005 ; 23 : 795-800.
    • (2005) Clin Exp Rheumatol , vol.23 , pp. 795-800
    • Cohen, G.1    Courvoisier, N.2    Cohen, J.D.3
  • 13
    • 75749106664 scopus 로고    scopus 로고
    • Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?
    • Finckh A, Ciurea A, Brulhart L, et al. Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent? Ann Rheum Dis 2010 ; 69 : 387-93.
    • Ann Rheum Dis , vol.2010 , Issue.69 , pp. 387-393
    • Finckh, A.1    Ciurea, A.2    Brulhart, L.3
  • 14
    • 70450202574 scopus 로고    scopus 로고
    • The reason for discontinuation of the first tumor necrosis factor (TNF) blocking agent does not influence the effect of a second TNF blocking agent in patients with rheumatoid arthritis
    • Blom M, Kievit W, Fransen J, et al. The reason for discontinuation of the first tumor necrosis factor (TNF) blocking agent does not influence the effect of a second TNF blocking agent in patients with rheumatoid arthritis. J Rheumatol 2009 ; 36 : 2171-7.
    • (2009) J Rheumatol , vol.36 , pp. 2171-2177
    • Blom, M.1    Kievit, W.2    Fransen, J.3
  • 15
    • 43049162899 scopus 로고    scopus 로고
    • Treatment response to a second or third TNF-inhibitor in RA: Results from the South Swedish Arthritis Treatment Group Register
    • Karlsson JA, Kristensen LE, Kapetanovic MC, et al. Treatment response to a second or third TNF-inhibitor in RA: results from the South Swedish Arthritis Treatment Group Register. Rheumatology 2008 ; 47 : 507-13.
    • (2008) Rheumatology , vol.47 , pp. 507-513
    • Karlsson, J.A.1    Kristensen, L.E.2    Kapetanovic, M.C.3
  • 16
    • 34347217850 scopus 로고    scopus 로고
    • Switching between anti-tumour necrosis factors: Trying to get a handle on a complex issue
    • van Vollenhoven RF. Switching between anti-tumour necrosis factors: trying to get a handle on a complex issue. Ann Rheum Dis 2007 ; 66 : 849-51.
    • (2007) Ann Rheum Dis , vol.66 , pp. 849-851
    • Van Vollenhoven, R.F.1
  • 17
    • 34347225530 scopus 로고    scopus 로고
    • Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: The opposite study
    • Furst DE, Gaylis N, Bray V, et al. Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study. Ann Rheum Dis 2007 ; 66 : 893-9.
    • (2007) Ann Rheum Dis , vol.66 , pp. 893-899
    • De, F.1    Gaylis, N.2    Bray, V.3
  • 18
    • 56749132218 scopus 로고    scopus 로고
    • Updated consensus statement on biological agents for the treatment of rheumatic diseases
    • 2008
    • Furst D E, Keystone EC, Kirkham B, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008. Ann Rheum Dis 2008 ; 67 ( Suppl 3 ): iii2 - 25.
    • (2008) Ann Rheum Dis , vol.67 , Issue.SUPPL 3
    • Furst, D.E.1    Keystone, E.C.2    Kirkham, B.3
  • 19
    • 27744533609 scopus 로고    scopus 로고
    • Infliximab to etanercept switch in patients with spondyloarthropathies and psoriatic arthritis: Preliminary data
    • Delaunay C, Farrenq V, Marini-Portugal A, et al. Infliximab to etanercept switch in patients with spondyloarthropathies and psoriatic arthritis: preliminary data. J Rheumatol 2005 ; 32 : 2183-5.
    • (2005) J Rheumatol , vol.32 , pp. 2183-2185
    • Delaunay, C.1    Farrenq, V.2    Marini-Portugal, A.3
  • 20
    • 33750318776 scopus 로고    scopus 로고
    • Switching from infliximab to once-weekly administration of 50 mg etanercept in resistant or intolerant patients with ankylosing spondylitis: Results of a fifty-four-week study
    • Cantini F, Niccoli L, Benucci M, et al. Switching from infliximab to once-weekly administration of 50 mg etanercept in resistant or intolerant patients with ankylosing spondylitis: results of a fifty-four-week study. Arthritis Rheum 2006 ; 55 : 812-16.
    • (2006) Arthritis Rheum , vol.55 , pp. 812-816
    • Cantini, F.1    Niccoli, L.2    Benucci, M.3
  • 21
    • 34848860252 scopus 로고    scopus 로고
    • Switching tumour necrosis factor alpha antagonists in patients with ankylosing spondylitis and psoriatic arthritis: An observational study over a 5-year period
    • Conti F, Ceccarelli F, Marocchi E, et al. Switching tumour necrosis factor alpha antagonists in patients with ankylosing spondylitis and psoriatic arthritis: an observational study over a 5-year period. Ann Rheum Dis 2007 ; 66 : 1393-7.
    • (2007) Ann Rheum Dis , vol.66 , pp. 1393-1397
    • Conti, F.1    Ceccarelli, F.2    Marocchi, E.3
  • 22
    • 70350605186 scopus 로고    scopus 로고
    • Switching TNF antagonists in patients with chronic arthritis: An observational study of 488 patients over a four-year period
    • Gomez-Reino JJ, Carmona L. Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. Arthritis Res Ther 2006 ; 8 : R29.
    • (2006) Arthritis Res Ther , vol.8
    • Gomez-Reino, J.J.1    Carmona, L.2
  • 23
    • 44849086068 scopus 로고    scopus 로고
    • Real life experience confirms sustained response to long-term biologics and switching in ankylosing spondylitis
    • Coates LC, Cawkwell LS, Ng NW, et al. Real life experience confirms sustained response to long-term biologics and switching in ankylosing spondylitis. Rheumatology 2008 ; 47 : 897-900.
    • (2008) Rheumatology , vol.47 , pp. 897-900
    • Coates, L.C.1    Cawkwell, L.S.2    Ng, N.W.3
  • 24
    • 54449099689 scopus 로고    scopus 로고
    • Switching anti-TNF therapy in ankylosing spondylitis
    • Pradeep DJ, Keat AC, Gaffney K, et al. Switching anti-TNF therapy in ankylosing spondylitis. Rheumatology 2008 ; 47 : 1726-7.
    • (2008) Rheumatology , vol.47 , pp. 1726-1727
    • Pradeep, D.J.1    Keat, A.C.2    Gaffney, K.3
  • 25
    • 66149125235 scopus 로고    scopus 로고
    • Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis
    • Rudwaleit M, Claudepierre P, Wordsworth P, et al. Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis. J Rheumatol 2009 ; 36 : 801-8.
    • (2009) J Rheumatol , vol.36 , pp. 801-808
    • Rudwaleit, M.1    Claudepierre, P.2    Wordsworth, P.3
  • 26
    • 77953505954 scopus 로고    scopus 로고
    • Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy
    • Rudwaleit M, Van den Bosch F, Kron M, et al. Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy. Arthritis Res Ther 2010 ; 12 : R117.
    • Arthritis Res Ther , vol.2010 , Issue.12
    • Rudwaleit, M.1    Van Den Bosch, F.2    Kron, M.3
  • 27
    • 0038423033 scopus 로고    scopus 로고
    • International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis
    • Braun J, Pham T, Sieper J, et al. International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis 2003 ; 62 : 817-24.
    • (2003) Ann Rheum Dis , vol.62 , pp. 817-824
    • Braun, J.1    Pham, T.2    Sieper, J.3
  • 28
    • 33144469246 scopus 로고    scopus 로고
    • First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis
    • Braun J, Davis J, Dougados M, et al. First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis 2006 ; 65 : 316-20.
    • (2006) Ann Rheum Dis , vol.65 , pp. 316-320
    • Braun, J.1    Davis, J.2    Dougados, M.3
  • 29
    • 33645124111 scopus 로고    scopus 로고
    • ASAS/EULAR recommendations for the management of ankylosing spondylitis
    • Zochling J, van der Heijde D, Burgos-Vargas R, et al. ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2006 ; 65 : 442-52.
    • (2006) Ann Rheum Dis , vol.65 , pp. 442-452
    • Zochling, J.1    Van Der Heijde, D.2    Burgos-Vargas, R.3
  • 30
    • 0028575453 scopus 로고
    • A new approach to defining disease status in ankylosing spondylitis: The Bath Ankylosing Spondylitis Disease Activity Index
    • Garrett S, Jenkinson T, Kennedy LG, et al. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994 ; 21 : 2286-91.
    • (1994) J Rheumatol , vol.21 , pp. 2286-2291
    • Garrett, S.1    Jenkinson, T.2    Kennedy, L.G.3
  • 31
    • 0028579768 scopus 로고
    • A new approach to defining functional ability in ankylosing spondylitis: The development of the Bath Ankylosing Spondylitis Functional Index
    • Calin A, Garrett S, Whitelock H, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994 ; 21 : 2281-5.
    • (1994) J Rheumatol , vol.21 , pp. 2281-2285
    • Calin, A.1    Garrett, S.2    Whitelock, H.3
  • 32
    • 0026877917 scopus 로고
    • The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection
    • Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992 ; 30 : 473-83.
    • (1992) Med Care , vol.30 , pp. 473-483
    • Ware Jr., J.E.1    Sherbourne, C.D.2
  • 33
    • 17144452769 scopus 로고    scopus 로고
    • Performance of the Norwegian SF-36 Health Survey in patients with rheumatoid arthritis. II. A comparison of the SF-36 with disease-specific measures
    • Kvien TK, Kaasa S, Smedstad LM. Performance of the Norwegian SF-36 Health Survey in patients with rheumatoid arthritis. II. A comparison of the SF-36 with disease-specific measures. J Clin Epidemiol 1998 ; 51 : 1077-86.
    • (1998) J Clin Epidemiol , vol.51 , pp. 1077-86
    • Kvien, T.K.1    Kaasa, S.2    Smedstad, L.M.3
  • 34
    • 0036169017 scopus 로고    scopus 로고
    • The estimation of a preference-based measure of health from the SF-36
    • Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ 2002 ; 21 : 271-92.
    • (2002) J Health Econ , vol.21 , pp. 271-292
    • Brazier, J.1    Roberts, J.2    Deverill, M.3
  • 35
    • 58349090431 scopus 로고    scopus 로고
    • Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis
    • Lukas C, Landewé R, Sieper J, et al. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis 2009 ; 68 : 18-24.
    • (2009) Ann Rheum Dis , vol.68 , pp. 18-24
    • Lukas, C.1    Landewé, R.2    Sieper, J.3
  • 36
    • 72249090182 scopus 로고    scopus 로고
    • ASDAS, a highly discriminatory ASASendorsed disease activity score in patients with ankylosing spondylitis
    • van der Heijde D, Lie E, Kvien TK, et al. ASDAS, a highly discriminatory ASASendorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis 2009 ; 68 : 1811-18.
    • (2009) Ann Rheum Dis , vol.68 , pp. 1811-1818
    • Van Der Heijde, D.1    Lie, E.2    Kvien, T.K.3
  • 37
    • 0034888069 scopus 로고    scopus 로고
    • Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis
    • Anderson JJ, Baron G, van der Heijde D, et al. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 2001 ; 44 : 1876-86.
    • (2001) Arthritis Rheum , vol.44 , pp. 1876-1886
    • Anderson, J.J.1    Baron, G.2    Van Der Heijde, D.3
  • 38
    • 78650657046 scopus 로고    scopus 로고
    • Ankylosing Spondylitis Disease Activity Score (ASDAS): Defining cut-off values for disease activity states and improvement scores
    • In Press
    • Machado P, Landewe R, Lie E, et al. Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis 2010 ;(In Press).
    • (2010) Ann Rheum Dis
    • MacHado, P.1    Landewe, R.2    Lie, E.3
  • 39
    • 0345490890 scopus 로고    scopus 로고
    • Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: Data from the STURE registry showing that switching tumour necrosis factor alpha blockers can make sense
    • van Vollenhoven R, Harju A, Brannemark S, et al. Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor alpha blockers can make sense. Ann Rheum Dis 2003 ; 62 : 1195-8.
    • (2003) Ann Rheum Dis , vol.62 , pp. 1195-1198
    • Van Vollenhoven, R.1    Harju, A.2    Brannemark, S.3
  • 40
    • 34247611914 scopus 로고    scopus 로고
    • Therapy of patients with rheumatoid arthritis: Outcome of infliximab failures switched to etanercept
    • Buch MH, Bingham SJ, Bejarano V, et al. Therapy of patients with rheumatoid arthritis: outcome of infliximab failures switched to etanercept. Arthritis Rheum 2007 ; 57 : 448-53.
    • (2007) Arthritis Rheum , vol.57 , pp. 448-453
    • Buch, M.H.1    Bingham, S.J.2    Bejarano, V.3
  • 41
    • 33846875483 scopus 로고    scopus 로고
    • Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects
    • Iannone F, Trotta F, Montecucco C, et al. Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects. Ann Rheum Dis 2007 ; 66 : 249-52.
    • (2007) Ann Rheum Dis , vol.66 , pp. 249-252
    • Iannone, F.1    Trotta, F.2    Montecucco, C.3
  • 42
    • 34447319146 scopus 로고    scopus 로고
    • Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice
    • Bombardieri S, Ruiz AA, Fardellone P, et al. Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice. Rheumatology 2007 ; 46 : 1191-9.
    • (2007) Rheumatology , vol.46 , pp. 1191-1199
    • Bombardieri, S.1    Ruiz, A.A.2    Fardellone, P.3
  • 43
    • 31144452536 scopus 로고    scopus 로고
    • Efficacy and safety of switching from infliximab to adalimumab: A comparative controlled study
    • Nikas SN, Voulgari PV, Alamanos Y, et al. Efficacy and safety of switching from infliximab to adalimumab: a comparative controlled study. Ann Rheum Dis 2006 ; 65 : 257-60
    • (2006) Ann Rheum Dis , vol.65 , pp. 257-260
    • Nikas, S.N.1    Voulgari, P.V.2    Alamanos, Y.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.